<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209206</url>
  </required_header>
  <id_info>
    <org_study_id>SeoulNUHUro</org_study_id>
    <nct_id>NCT03209206</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence</brief_title>
  <official_title>The Effectiveness and Safety of Intravesical Docetaxel Instillation After Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy or Distal Ureterectomy in Upper Urinary Tract Urothelial Carcinoma: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluated the efficacy of a single early intravesical instillation of
      doxetaxel in the prevention of bladder recurrence after nephroureterectomy or distal
      ureterectomy for upper urinary tract urothelial carcinoma (UUT-UC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 20% to 50% of patients with upper urinary tract urothelial carcinoma (UUT-UC)
      experience bladder recurrence after nephroureterectomy. Although many agents have been
      administered for the prevention of bladder recurrence, the standard prophylactic treatment
      has yet to be established. A meta-analysis found that a single instillation of chemotherapy
      immediately after transurethral resection of bladder tumor (TURBT) significantly decreased
      the risk of recurrence in patients with bladder cancer. Indeed, a single early instillation
      of Docetaxel was found to reduce the post-TURBT bladder recurrence rate among patients with
      bladder cancer.

      In this prospective, randomized study, the investigators evaluated the efficacy of a single,
      early, intravesical instillation of Docetaxel in the prevention of bladder recurrence after
      nephroureterectomy for UUT-UC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Phase II Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence in bladder</measure>
    <time_frame>2years</time_frame>
    <description>Present of bladder recurrence after intervention in follow up cystoscopy or CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>2years</time_frame>
    <description>Present of adverse event after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2years</time_frame>
    <description>Overall Survival rate during follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>2years</time_frame>
    <description>Time to bladder recurrence after intervention in follow up cystoscopy or CT scan</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel bladder instillation arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)</description>
    <arm_group_label>Docetaxel bladder instillation arm</arm_group_label>
    <other_name>Instillation docetaxel after radical nephroureterectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Normal saline</intervention_name>
    <description>Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>Instillation Normal saline after radical nephroureterectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper urinary tract urothelial cell carcinoma

          -  Hb&gt;10g/dL, ANC &gt;1500mm3, Platelet &gt; 100K

          -  Total bilirubin : 1.5 times lower than the normal upper limit

          -  AST/ALT: 1.8 times lower than the normal upper limit

          -  Alkaline phosphatase: 1.8 times lower than the normal upper limit

        Exclusion Criteria:

          -  Concomitant bladder tumor

          -  Patients diagnosed with bladder cancer within the last 3 years

          -  Previous history of hypersensitivity to Docetaxel

          -  Neurogenic Bladder

          -  Patients who received chemotherapy for cancer within the last 6 months

          -  Patients with active disease not fit for this study

          -  ANC &lt;1500mm3

          -  Pregnant or lactating women

          -  Patients with severe hepatic dysfunction

          -  patients with severe renal impairment

          -  patients with hypersensitivity to mannitol, paraplatin, platinum compounds

          -  Patients with complications of infection

          -  Patients suspected of having infectious fever
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ja Hyeon Ku, M.D.,PH.D</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ja Hyeon Ku, M.D.,PH.D</last_name>
    <phone>+82-2-2072-0361</phone>
    <email>randyku@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bum Sik Tae, M.D</last_name>
    <phone>+82-10-9056-6618</phone>
    <email>bumsik4ever@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja Hyeon Ku, M.D, Ph.D</last_name>
      <phone>82-2-2072-0361</phone>
      <email>randyku@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Bum Sik Tae, M.D</last_name>
      <phone>82-2-2072-0361</phone>
      <email>bumsik4ever@hanmail.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013 Apr 10;31(11):1422-7. doi: 10.1200/JCO.2012.45.2128. Epub 2013 Mar 4.</citation>
    <PMID>23460707</PMID>
  </results_reference>
  <results_reference>
    <citation>Delto JC, Kobayashi T, Benson M, McKiernan J, Abate-Shen C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget. 2013 Feb;4(2):269-76.</citation>
    <PMID>23563166</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu P, Zhu G, Wei D, Liu S, Walsh K, Li D, Harron U, Wang X, Ma H, Wan B, Sun L, Yang Z, Wang J. Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: A systematic review and meta-analysis. J BUON. 2015 Sep-Oct;20(5):1229-38. Review.</citation>
    <PMID>26537069</PMID>
  </results_reference>
  <results_reference>
    <citation>Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2010 Jan;75(1):134-7. doi: 10.1016/j.urology.2009.06.112. Epub 2009 Nov 13.</citation>
    <PMID>19913890</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu S, Neoh KG, Kang ET, Mahendran R, Chiong E. Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. Eur J Pharm Sci. 2015 May 25;72:57-68. doi: 10.1016/j.ejps.2015.03.006. Epub 2015 Mar 13.</citation>
    <PMID>25772330</PMID>
  </results_reference>
  <results_reference>
    <citation>Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Gu√©rin therapy. BJU Int. 2009 Oct;104(8):1098-102. doi: 10.1111/j.1464-410X.2009.08543.x. Epub 2009 Apr 15.</citation>
    <PMID>19389012</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ja Hyeon Ku</investigator_full_name>
    <investigator_title>Professor, MD., PHD.</investigator_title>
  </responsible_party>
  <keyword>Intravesical Chemotherapy</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Radical Nephroureterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

